title: Acetylsalicylic acid (ASA) use among Polish adults with diabetes mellitus.
abstract: People with diabetes mellitus have higher risk of cardiovascular morbidity and mortality from thrombo-vascular complications than non-diabetics and it is recommended that they should use acetylsalicylic acid (ASA) as anitiplatelet agent regularly. The aim of this study was to examine current physician counseling about ASA therapy and the use of ASA by Polish patients with diabetes. The study involved 464 randomly selected Caucasian diabetic individuals, mainly with type 2 (>98%), who were asked to complete a questionnaire consisting of 16 questions while visiting out-patient medical centres for periodical examination or during hospitalization. We collected data on the prevalence of cardiovascular disease (CVD), frequency of risk factors among diabetic patients and on ASA physician counseling, and on the rate of regular ASA users among the patients. The most self-reported conditions were angina pectoris or prior myocardial infarction (63,6%). Current cigarette smoking was declared by 7,1% of the patients, elevated serum cholesterol levels by 58%, and hypertension by 62,9%. Majority of the patients were overweight, and family history of coronary artery disease (CAD) was reported by 30,2% of the patients. ASA was taken by 67,2% of all the patients and 72,1% of them had taken ASA regularly. The highest percentage (>80%) of regular ASA users was found among diabetic patients with CAD. A minority of the patients who reported stroke (43,9%) or claudication (15,8%) were taking ASA regularly. Number of the patients (32,8%) with CVD risk factor(s) but without diagnosed CVD did not use ASA at all. The majority of the patients (78%) were counseled by their physicians why they should use ASA regularly.
  
  
  CONCLUSIONS
  the number of regular users of ASA among diabetic patients in Poland with CVD others than CAD or among patients with at least two CAD risk factors is still unsatisfactory. Therefore, while it seems that there is a remarkable growing of ASA therapy world-wide more effort is needed to make this practice a standard of multifactorial, intensive diabetes treatment. Our results also suggest the need for more aggressive education of both doctors and patients.
authors.affiliation: Department of Diabetology and Clinical Pharmacology. Medical University of Lodz. jdrzew@poczta.onet.pl
authors.forename: Jozef
authors.initials: J
authors.lastname: Drzewoski
authors.forename: Joanna
authors.initials: J
authors.lastname: Sawer-Szewczyk
authors.forename: Anna
authors.initials: A
authors.lastname: Stepień
authors.forename: Andrzej
authors.initials: A
authors.lastname: Olszewski
authors.forename: Marek
authors.initials: M
authors.lastname: Liniarski
mesh_terms: D000328:Adult; D001241:Aspirin / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D015984:Causality; D015897:Comorbidity; D048909:Diabetes Complications / Q000188:drug therapy*; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000453:epidemiology; D004363:Drug Utilization; D005260:Female; D006266:Health Education / Q000592:standards; D006293:Health Promotion / Q000592:standards; D006306:Health Surveys; D006801:Humans; D008297:Male; D008875:Middle Aged; D011044:Poland; D015995:Prevalence; D012307:Risk Factors
chemical_list: D001241:Aspirin